secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0001628280-22-000561
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Therapeutics appoints Steven Bellon as CSO; Carl Decicco to retire by Jan 31, 2022
--------------------------------------------------------------------------------

- Carl Decicco steps down as CSO effective Jan 10, 2022; serves as Special Advisor through Jan 31, 2022 then retires.
- Steven Bellon, PhD appointed as CSO effective Jan 10, 2022; joined Foghorn in 2016 as head of drug discovery.
- Bellon brings 20+ years drug discovery experience from Amgen, Vertex, and Constellation Pharmaceuticals.
- Decicco will receive base salary through Jan 31, 2022 and is eligible for FY2021 bonus; vested options exercisable until July 5, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828022000561/0001628280-22-000561-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828022000561/fhtx-20220110.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-000561

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer